Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0WZSSJ
ADC Name	TWEAKR-KSPi-ADC1
Synonyms	TWEAKR KSPi ADC1 Click to Show/Hide
Drug Status	Investigative
Indication	In total 6 Indication(s) Breast cancer [ICD11:2C60-2C65] Investigative Colorectal cancer [ICD11:2B91] Investigative Endometrial cancer [ICD11:2C76] Investigative Glioblastoma [ICD11:2A00] Investigative Lung cancer [ICD11:2C25] Investigative Ovarian cancer [ICD11:2C73] Investigative
	3D MOL	2D MOL
Antibody Name	BAY-356		Antibody Info
Antigen Name	Tumor necrosis factor receptor superfamily member 12A (TNFRSF12A)		Antigen Info
Payload Name	KSP inhibitor		Payload Info
Therapeutic Target	Kinesin-like protein KIF11 (KIF11)		Target Info
Linker Name	Glutaricacid-peptide-based linker		Linker Info

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 80	%	CT26 cells	Colon carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 80.00% (Day 17)	Positive CTLA4 expression (CTLA4 +++/++)
Method Description	To exclude anti-tumor effects based on the agonistic activity of the anti-TWEAKR antibody, a maximum dose of 5 mg/kg biweekly was chosen for investigating the anti-tumor activity of TWEAKR-KSPi-ADC1 in mice bearing CT26 tumors.
In Vivo Model	CT26 CDX model
In Vitro Model	Colon carcinoma	CT26 cells		CVCL_7254

References

Ref 1	Antibody-drug conjugates harboring a kinesin spindle protein inhibitor with immunostimulatory properties. Oncoimmunology. 2022 Feb 9;11(1):2037216. doi: 10.1080/2162402X.2022.2037216.